Search

Your search keyword '"Kamat, A.M."' showing total 160 results

Search Constraints

Start Over You searched for: Author "Kamat, A.M." Remove constraint Author: "Kamat, A.M."
160 results on '"Kamat, A.M."'

Search Results

Catalog

Books, media, physical & digital resources

6. Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial

7. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

9. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.

10. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses.

14. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

15. Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group.

16. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group

18. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group

23. A0583 - Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial

24. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)

27. Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses

28. 718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

29. Data sharing under the general data protection regulation: Time to harmonize law and research ethics?

30. Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

32. Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

33. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

34. 100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19

35. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?

36. Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis

37. Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

38. What is the prognostic importance of urothelial and non-urothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? Systematic review

41. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

42. Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)

43. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis

44. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer

45. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

47. Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)

48. Outcomes of radical cystectomy following implementation of enhanced recovery after surgery protocols: A systematic review